CY1111925T1 - Κιναση της θυμιδινης - Google Patents

Κιναση της θυμιδινης

Info

Publication number
CY1111925T1
CY1111925T1 CY20111100964T CY111100964T CY1111925T1 CY 1111925 T1 CY1111925 T1 CY 1111925T1 CY 20111100964 T CY20111100964 T CY 20111100964T CY 111100964 T CY111100964 T CY 111100964T CY 1111925 T1 CY1111925 T1 CY 1111925T1
Authority
CY
Cyprus
Prior art keywords
nucleotides
thymidine
movement
polynucleotide
replaced
Prior art date
Application number
CY20111100964T
Other languages
English (en)
Original Assignee
Molmed Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32750189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111925(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Molmed Spa filed Critical Molmed Spa
Publication of CY1111925T1 publication Critical patent/CY1111925T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Ένα πολυνουκλεοτίδιο που περιλαμβάνει μια αλληλουχία νουκλεοτιδίων που κωδικοποιεί μια κινάση της θυμιδίνης όπου τουλάχιστον ένα από τα νουκλεοτίδια που αντιστοιχεί στα νουκλεοτίδια της θέσης ματίσματος του δότη αντικαθίσταται από ένα άλλο νουκλεοτίδιο και όπου τα νουκλεοτίδια των θέσεων ματίσματος του λήπτη δεν είναι αλλοιωμένα.
CY20111100964T 2004-06-18 2011-10-10 Κιναση της θυμιδινης CY1111925T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0413702.2A GB0413702D0 (en) 2004-06-18 2004-06-18 Thymidine kinase
EP05766582A EP1781789B1 (en) 2004-06-18 2005-06-17 Thymidine kinase

Publications (1)

Publication Number Publication Date
CY1111925T1 true CY1111925T1 (el) 2015-11-04

Family

ID=32750189

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100964T CY1111925T1 (el) 2004-06-18 2011-10-10 Κιναση της θυμιδινης
CY2016054C CY2016054I1 (el) 2004-06-18 2016-12-28 Κιναση της θυμιδινης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2016054C CY2016054I1 (el) 2004-06-18 2016-12-28 Κιναση της θυμιδινης

Country Status (20)

Country Link
US (5) US8357788B2 (el)
EP (1) EP1781789B1 (el)
JP (1) JP5091669B2 (el)
KR (1) KR101337210B1 (el)
CN (1) CN101010428B (el)
AT (1) ATE520779T1 (el)
AU (1) AU2005254807B2 (el)
CA (1) CA2569304C (el)
CY (2) CY1111925T1 (el)
DK (1) DK1781789T3 (el)
ES (1) ES2372022T3 (el)
GB (1) GB0413702D0 (el)
HU (1) HUS1600064I1 (el)
IL (2) IL179660A (el)
LT (1) LTC1781789I2 (el)
NL (1) NL300856I2 (el)
PL (1) PL1781789T3 (el)
PT (1) PT1781789E (el)
SI (1) SI1781789T1 (el)
WO (1) WO2005123912A2 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase
CN103842501B (zh) 2011-10-05 2017-12-08 莫尔梅德股份有限公司 病毒载体纯化系统
KR102077648B1 (ko) * 2017-12-28 2020-02-14 주식회사 바이오녹스 안전성 및 항암효과가 개선된 종양 용해 바이러스
US11157042B1 (en) 2018-03-28 2021-10-26 Douglas Patton Systems and methods for interaction of wearable communication devices
EP3802796A1 (en) 2018-05-30 2021-04-14 Glycostem Therapeutics B.V. Car nk cells
AU2020306544B2 (en) * 2019-06-27 2025-10-16 Bionoxx Inc. Oncolytic virus with improved safety and anticancer effects
WO2025168661A1 (en) 2024-02-05 2025-08-14 Ospedale San Raffaele S.R.L. Chimeric antigen receptor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
DE69032841T2 (de) 1989-01-23 1999-05-12 Chiron Corp., Emeryville, Calif. Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
IT1261847B (it) 1993-09-01 1996-06-03 San Romanello Centro Fond Metodo per marcare cellule eucariote.
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
ATE211174T1 (de) 1994-05-02 2002-01-15 Univ Washington Thymidin-kinase-mutanten
FR2744731B1 (fr) 1996-02-09 1998-05-22 Rhone Poulenc Rorer Sa Nouveaux variants de la thymidine kinase, sequences d'acides nucleiques correspondantes et leur utilisation en therapie genique
FR2751988B1 (fr) 1996-08-01 1998-09-11 Rhone Poulenc Rorer Sa Nouveaux variants de la thymidine kinase, sequences d'acides nucleiques correspondantes et leur utilisation en therapie genique
WO1997029196A1 (fr) 1996-02-09 1997-08-14 Rhone-Poulenc Rorer S.A. Variants de la thymidine kinase, sequences d'acides nucleiques correspondantes et leur utilisation en therapie genique
AU726584B2 (en) 1996-04-10 2000-11-09 University Of Southern California Gene therapy for proliferative vitreoretinopathy
EP2298350A3 (en) 1996-07-26 2011-06-08 Susan P. Perrine Composition comprising an inducing agent and an anti-viral agent for the treatment of viral disorders
EP2386630A1 (en) 1997-10-14 2011-11-16 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
GB0008966D0 (en) * 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
CN1273587C (zh) * 2002-06-05 2006-09-06 上海新世界基因技术开发有限公司 疱疹病毒胸苷激酶突变体及其应用
DE50213745D1 (de) 2002-12-09 2009-09-17 Celltech Gmbh Biotechnologie Verbesserte retrovirale Vektoren für die Gentherapie
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase

Also Published As

Publication number Publication date
IL213084A0 (en) 2011-07-31
WO2005123912A3 (en) 2006-05-04
CN101010428B (zh) 2013-10-02
WO2005123912A2 (en) 2005-12-29
GB0413702D0 (en) 2004-07-21
US9005945B2 (en) 2015-04-14
PT1781789E (pt) 2011-10-20
US20150231275A1 (en) 2015-08-20
SI1781789T1 (sl) 2012-03-30
US10155052B2 (en) 2018-12-18
PL1781789T3 (pl) 2011-12-30
HUS1600064I1 (hu) 2017-02-28
KR20070032786A (ko) 2007-03-22
US8642311B2 (en) 2014-02-04
HK1097881A1 (en) 2007-07-06
US20130028876A1 (en) 2013-01-31
CA2569304C (en) 2014-08-12
CY2016054I2 (el) 2017-07-12
CA2569304A1 (en) 2005-12-29
US20090130069A1 (en) 2009-05-21
ATE520779T1 (de) 2011-09-15
EP1781789B1 (en) 2011-08-17
IL179660A0 (en) 2007-05-15
KR101337210B1 (ko) 2013-12-06
JP5091669B2 (ja) 2012-12-05
NL300856I2 (el) 2017-04-20
US8357788B2 (en) 2013-01-22
LTPA2016047I1 (lt) 2017-01-25
IL179660A (en) 2012-12-31
US10314925B2 (en) 2019-06-11
LTC1781789I2 (lt) 2018-10-10
EP1781789A2 (en) 2007-05-09
CY2016054I1 (el) 2017-07-12
AU2005254807A1 (en) 2005-12-29
JP2008502342A (ja) 2008-01-31
US20190070312A1 (en) 2019-03-07
ES2372022T3 (es) 2012-01-13
AU2005254807B2 (en) 2011-08-18
DK1781789T3 (da) 2011-11-28
CN101010428A (zh) 2007-08-01
US20140178345A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
CY1111925T1 (el) Κιναση της θυμιδινης
CY2018019I2 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
DK3587433T3 (da) Modificerede nukleotider
CY2016052I2 (el) Τροποποιημενα φθοριομενα αναλογα νουκλεοζιδιων
LTC1849470I2 (lt) Priešvėžinis vaistas, turintis alfa, alfa, alfa-trifluortimidino ir timidinfosforilazės inhibitorių
CY1117139T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις πρωτεϊνης κινασης τυροσινης
DK3266791T3 (da) Mærkede nukleotider
EP1660512A4 (en) SYNTHESIS OF OLIGONUCLEOTIDES USING ALTERNATIVE SOLVENTS
BRPI0817265A2 (pt) Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada
EP1497655A4 (en) IMPROVED GENE EXPRESSION SYSTEM
ATE538127T1 (de) 6-disubstituierte bicyclische nukleinsäureanaloga
DK1957528T3 (da) Nukleotid-vaccine
DK2354148T3 (da) Nukleosidanaloger og oligonukleotiderivate omfattende nukleotidanalog deraf
DK1673352T3 (da) Sulfoximinsubstituerede pyrimidiner som CDK- og/eller VEGF-inhibitorer, deres fremstilling og anvendelse som lægemiddel
DE602005020229D1 (de) Schaufel mit prallgekühltem Übergang von grossem Krümmungsradius
BRPI0412856A2 (pt) trava extensível de múliplos pontos aperfeiçoada
NO20054405D0 (no) Kjemokinreseptor-binende heterosykel
CR8385A (es) Pirimidinas sustituidas con sulfoximina como inhibidores de cdk y/o vegf, su preparacion y sus usos como medicamento
DK1765844T3 (da) Purin-nukleotidderivater
DE602004029903D1 (de) Tunnelübergangselement
LU91032B1 (de) Mauerstein.
ITFI20040173A1 (it) Profarmaci attivati da dna polimerasi dipendenti da rna
ITTO20030815A1 (it) Procedimento per la produzione di maglieria di tipo tubolare.
BR8202159Y1 (pt) disposição construtiva aplicada em tijolo.
ITPD20030144A1 (it) Pannello di comando touch control di tipo capacitivo